首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

癌症基因治療市場規模、佔有率和成長分析（按類型、治療方法、產品類型、最終用途和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1900427

癌症基因治療市場規模、佔有率和成長分析（按類型、治療方法、產品類型、最終用途和地區分類）—2026-2033年產業預測

Cancer Gene Therapy Market Size, Share, and Growth Analysis, By Type (Ex-Vivo, In-Vivo), By Therapy (Oncolytic Virotherapy, Gene-Induced Immunotherapy), By Product, By End Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球癌症基因治療市場規模預計在 2024 年達到 42.5 億美元，從 2025 年的 51.6 億美元成長到 2033 年的 243.4 億美元，在預測期（2026-2033 年）內複合年成長率為 21.4%。

全球癌症發生率的快速成長是推動癌症基因治療市場成長的主要因素。對創新癌症治療方法的需求不斷成長，加上基因工程技術的進步和對新型治療方法的巨額投資，預計將顯著提振市場需求。基因技術的持續進步及其在腫瘤學應用研究的活性化，正激勵企業開發突破性的癌症基因療法。此外，人們越來越傾向於選擇旨在提高存活率的個人化癌症治療方案，加上政府對癌症患者的資助，預計將為該領域的參與者帶來新的機會。然而，高昂的治療成本、潛在的副作用以及複雜的生產製造等挑戰，可能會阻礙癌症基因治療市場的長期發展。

全球癌症基因治療市場促進因素

全球癌症基因治療市場正經歷顯著成長，這主要得益於基因工程和基因組定序技術的進步，而這些技術的進步又得益於對基因研究舉措的大量投資。這些基因領域的創新進展正日益融入癌症研究，進而催生出突破性的癌症基因療法。這種融合不僅提高了癌症治療的有效性，也拓寬了患者的治療選擇，最終推動了市場的發展。隨著研究的不斷深入，新型和改良型基因療法在對抗癌症方面的潛力預計將持續光明。

限制全球癌症基因治療市場的因素

全球癌症基因治療市場面臨的主要挑戰之一是這些先進療法的高成本，導致許多患者無法獲得治療。相關技術的複雜性以及研發所需的大量投資是造成高成本的主要原因。因此，經濟障礙限制了癌症基因療法的廣泛應用，並非所有患者都能獲得這些創新療法。這個經濟問題阻礙了基因療法融入標準癌症治療體系的進程，最終影響了整個產業有效治療方案的成長和普及。

全球癌症基因治療市場趨勢

全球癌症基因治療市場正經歷一個顯著趨勢：對聯合治療的需求日益成長，這主要源於越來越多的癌症患者尋求先進治療方法以提高存活率。為了因應這一轉變，基因治療供應商正不斷創新，開發新的聯合治療，探索不同治療方法的協同效應，從而擴大市場佔有率並改善患者預後。隨著醫療專業人員越來越重視個人化醫療和客製化治療通訊協定，癌症基因治療領域對聯合治療的關注為企業創造了巨大的成長機遇，使其在不斷發展的腫瘤學領域中處於領先地位。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Novartis AG（Switzerland）
Gilead Sciences, Inc.（USA）
Bristol Myers Squibb Company（USA）
CRISPR Therapeutics（Switzerland）
Amgen Inc.（USA）
Merck KGaA（Germany）
Intellia Therapeutics, Inc.（USA）
Adaptimmune Therapeutics（UK）
Autolus Therapeutics（UK）
Sangamo Therapeutics, Inc.（USA）
Vertex Pharmaceuticals（USA）
Abeona Therapeutics Inc.（USA）
Johnson & Johnson（USA）
Pfizer Inc.（USA）
AstraZeneca（UK）
Takeda Pharmaceutical Company Limited（Japan）

結論與建議

簡介目錄

Product Code: SQMIG35G2180

Global Cancer Gene Therapy Market size was valued at USD 4.25 Billion in 2024 and is poised to grow from USD 5.16 Billion in 2025 to USD 24.34 Billion by 2033, growing at a CAGR of 21.4% during the forecast period (2026-2033).

The surge in global cancer incidence is a primary catalyst for the growth of the cancer gene therapy market. The increasing demand for innovative cancer treatments, coupled with advancements in genetic engineering and substantial investments in new therapies, is expected to significantly boost market demand. Ongoing progress in gene technologies and heightened research into their oncology applications are encouraging companies to create groundbreaking cancer gene therapies. Furthermore, the rising preference for personalized cancer treatments aimed at improving survival rates, along with supportive government funding for cancer patients, is anticipated to open up new opportunities for providers in this sector. However, challenges such as high treatment costs, potential adverse reactions, and manufacturing complexities could hinder the long-term development of the cancer gene therapy market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Gene Therapy Market Segments Analysis

Global Cancer Gene Therapy Market is segmented by Type, Therapy, Product, End Use and region. Based on Type, the market is segmented into Ex-Vivo and In-Vivo. Based on Therapy, the market is segmented into Oncolytic Virotherapy, Gene-Induced Immunotherapy and Gene Transfer. Based on Product, the market is segmented into Viral Vectors, Non-Viral Vectors and Other Products. Based on End Use, the market is segmented into Biopharma Companies, Research Institutes and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is experiencing significant growth, largely fueled by advancements in genetic engineering and genome mapping technologies, which have benefited from substantial investments in gene research initiatives. These innovative developments in genetics are increasingly being incorporated into oncology research, leading to the creation of groundbreaking cancer gene therapies. This integration not only enhances the effectiveness of cancer treatments but also broadens the therapeutic options available to patients, ultimately propelling the market forward. As research continues to evolve, the potential for new and improved gene therapies in the fight against cancer remains promising.

Restraints in the Global Cancer Gene Therapy Market

One significant challenge facing the Global Cancer Gene Therapy market is the high cost associated with these advanced treatments, which often makes them inaccessible for many patients. The intricacy of the technology involved and the considerable investment required for development contribute to these elevated expenses. Consequently, the financial barrier limits the widespread adoption of cancer gene therapy, as not all patients can afford these innovative options. This affordability issue hampers the progress of integrating gene therapy into standard cancer care, ultimately affecting the overall growth and accessibility of effective treatment alternatives within the industry.

Market Trends of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is witnessing a notable trend toward the increasing demand for combination therapies, driven by a rising prevalence of cancer patients seeking enhanced treatment options to improve survival rates. This shift is prompting gene therapy providers to innovate and develop new combination therapies that synergize the efficacy of various treatment modalities, thereby expanding their market presence and enhancing patient outcomes. As healthcare professionals emphasize personalized medicine and tailored treatment protocols, the focus on combination therapies in cancer gene therapy creates substantial growth opportunities for companies, positioning them at the forefront of the evolving oncology landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Cancer Gene Therapy Market Size by Type & CAGR (2026-2033)

Market Overview
Ex-Vivo
In-Vivo

Global Cancer Gene Therapy Market Size by Therapy & CAGR (2026-2033)

Market Overview
Oncolytic Virotherapy
Gene-Induced Immunotherapy
Gene Transfer

Global Cancer Gene Therapy Market Size by Product & CAGR (2026-2033)

Market Overview
Viral Vectors
- Adenoviruses
- Lentiviruses
- Retrovirus
- Adeno Associated Virus
- Herpes Simplex Virus
- Vaccinia Virus
- Other Viral Vectors
Non-Viral Vectors
Other Products

Global Cancer Gene Therapy Market Size by End Use & CAGR (2026-2033)

Market Overview
Biopharma Companies
Research Institutes
Other End-Users

Global Cancer Gene Therapy Market Size & CAGR (2026-2033)

North America (Type, Therapy, Product, End Use)
- US
- Canada
Europe (Type, Therapy, Product, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Therapy, Product, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Therapy, Product, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Therapy, Product, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intellia Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptimmune Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Autolus Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abeona Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments